Average Insider

Where insiders trade, we follow

$PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
James G. McArthur
CEO
79
Employees
$1.83
Current Price
$444.73M
Market Cap
52W Low$1.01
Current$1.8312.1% above low, 87.9% below high
52W High$7.80

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00--All Sells
Sells11$1,739.391,233
3 monthsBuys00--All Sells
Sells11$1,739.391,233
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
May 21, 2026
Kasraian Kasra
Chief Technical Officer
Sale1,233$1.41$1,739.39View Details
8 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.5.2